相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells
Emilie Cayssials et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice
Carmen Fava et al.
HAEMATOLOGICA (2019)
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
Simona Bernardi et al.
CANCER MEDICINE (2019)
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis
Kang-kang Chen et al.
FRONTIERS IN ONCOLOGY (2019)
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
Susan Branford et al.
LEUKEMIA (2019)
Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission
Pierre-Yves Dumas et al.
CANCER MEDICINE (2019)
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial
Richard E. Clark et al.
LANCET HAEMATOLOGY (2019)
Monitoring and Analysis of Chinese Chronic Myeloid Leukemia Patients Who Have Stopped Tyrosine Kinase Inhibitor Therapy
Na Shen et al.
CURRENT MEDICAL SCIENCE (2019)
Treatment-free remission with first- and second-generation tyrosine kinase inhibitors
Jorge Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
Niklas Landberg et al.
HAEMATOLOGICA (2018)
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
Niklas Landberg et al.
HAEMATOLOGICA (2018)
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase
Francois-Xavier Mahon et al.
ANNALS OF INTERNAL MEDICINE (2018)
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
Jorge E. Cortes et al.
BLOOD (2018)
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
Susan Branford et al.
BLOOD (2018)
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Recommendations for Clinical Practice From the French Chronic Myeloid Leukemia Study Group
Delphine Rea et al.
CANCER (2018)
Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective
Giuseppe Saglio et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele et al.
LANCET ONCOLOGY (2018)
Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia
Massimo Breccia et al.
CURRENT ONCOLOGY REPORTS (2018)
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
Joseph Schoepfer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
Juan Carlos Hernandez-Boluda et al.
BLOOD CANCER JOURNAL (2018)
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
David M. Ross et al.
LEUKEMIA (2018)
Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy
TaeHyung Kim et al.
BLOOD (2017)
CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression
Anuradha Tarafdar et al.
BLOOD (2017)
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
M. Ilander et al.
LEUKEMIA (2017)
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
Delphine Rea et al.
HAEMATOLOGICA (2017)
Introduction: MHC/KIR and governance of specificity
Adrian Kelly et al.
IMMUNOGENETICS (2017)
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
Gabriel Etienne et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
C. Schuetz et al.
LEUKEMIA (2017)
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
A. Hochhaus et al.
LEUKEMIA (2017)
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
R. Hehlmann et al.
LEUKEMIA (2017)
Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much
Robert Peter Gale et al.
LEUKEMIA RESEARCH (2017)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Immune control in chronic myeloid leukemia
Mette Ilander et al.
ONCOTARGET (2017)
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
Delphine Rea et al.
HAEMATOLOGICA (2017)
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
Amy Hughes et al.
FRONTIERS IN IMMUNOLOGY (2017)
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial
Richard E. Clark et al.
LANCET HAEMATOLOGY (2017)
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment
Ghayas C. Issa et al.
BLOOD (2017)
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Hochhaus et al.
ANNALS OF ONCOLOGY (2017)
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Tessa L. Holyoake et al.
BLOOD (2017)
Allogeneic transplantation for CML in the TKI era: striking the right balance
Andrew J. Innes et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Moving treatment-free remission into mainstream clinical practice in CML
Timothy P. Hughes et al.
BLOOD (2016)
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
Charles A. Schiffer et al.
CANCER (2016)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Jeffrey H. Lipton et al.
LANCET ONCOLOGY (2016)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A. Hochhaus et al.
LEUKEMIA (2016)
The concept of treatment-free remission in chronic myeloid leukemia
S. Saussele et al.
LEUKEMIA (2016)
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
J. L. Steegmann et al.
LEUKEMIA (2016)
Immunological off-target effects of imatinib
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study
Noriyoshi Iriyama et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study
Silvia Mori et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death
Markus Pfirrmann et al.
ANNALS OF HEMATOLOGY (2015)
KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy
David T. Yeung et al.
BLOOD (2015)
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients
Giovanni Caocci et al.
EXPERIMENTAL HEMATOLOGY (2015)
Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study
Franck E. Nicolini et al.
LANCET HAEMATOLOGY (2015)
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
Timothy P. Hughes et al.
BLOOD (2014)
DPPIV (CD26) as a novel stem cell marker in Ph plus chronic myeloid leukaemia
Peter Valent et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2014)
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
Sung-Hyun Kim et al.
HAEMATOLOGICA (2014)
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
B. Hanfstein et al.
LEUKEMIA (2014)
Sex differences in the incidence of chronic myeloid leukemia
Tomas Radivoyevitch et al.
RADIATION AND ENVIRONMENTAL BIOPHYSICS (2014)
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients
Giorgio La Nasa et al.
EXPERIMENTAL HEMATOLOGY (2013)
Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
Bengt Simonsson et al.
BLOOD (2011)
Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD
G. C. Hildebrandt et al.
BONE MARROW TRANSPLANTATION (2011)
Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay
Hyun-Gyung Goh et al.
LEUKEMIA & LYMPHOMA (2011)
The response to imatinib and interferon-α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase
Francesca Palandri et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
Andreas Burchert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
D. M. Ross et al.
LEUKEMIA (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Chronic Myeloid Leukemia: A Historical Perspective
John M. Goldman
SEMINARS IN HEMATOLOGY (2010)
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib
Agnes S. M. Yong et al.
BLOOD (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
INFLUENCE OF LATE TREATMENT ON HOW CHRONIC MYELOID LEUKEMIA RESPONDS TO IMATINIB
Ana Carolina Costa Scerni et al.
CLINICS (2009)
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
L. L. Remsing Rix et al.
LEUKEMIA (2009)
Understanding and harnessing the graft-versus-leukaemia effect
A. John Barrett
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy
A. S. M. Yong et al.
LEUKEMIA (2008)
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure
Alice Fabarius et al.
HAEMATOLOGICA (2007)
The kinase inhibitor imatinib - An immunosuppressive drug?
D. Wolf et al.
CURRENT CANCER DRUG TARGETS (2007)
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Philippe Rousselot et al.
BLOOD (2007)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
E. Weisberg et al.
BRITISH JOURNAL OF CANCER (2006)
Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?
J Goldman et al.
LEUKEMIA & LYMPHOMA (2006)
Dynamics of chronic myeloid leukaemia
F Michor et al.
NATURE (2005)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission
MJ Mauro et al.
LEUKEMIA RESEARCH (2004)
Mechanisms of disease - Chronic myeloid leukemia - Advances in biology and new approaches to treatment
JM Goldman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
分享论文
